The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme
A high percentage of malignant gliomas are infected by human cytomegalovirus (HCMV), and the endogenous expression of HCMV genes and their products are found in these tumors. HCMV antigen expression and its implications in gliomagenesis have emerged as a promising target for adoptive cellular immuno...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.818447/full |
| _version_ | 1818271787250614272 |
|---|---|
| author | Amin Daei Sorkhabi Amin Daei Sorkhabi Aila Sarkesh Aila Sarkesh Hossein Saeedi Faroogh Marofi Mahnaz Ghaebi Nicola Silvestris Behzad Baradaran Behzad Baradaran Oronzo Brunetti |
| author_facet | Amin Daei Sorkhabi Amin Daei Sorkhabi Aila Sarkesh Aila Sarkesh Hossein Saeedi Faroogh Marofi Mahnaz Ghaebi Nicola Silvestris Behzad Baradaran Behzad Baradaran Oronzo Brunetti |
| author_sort | Amin Daei Sorkhabi |
| collection | DOAJ |
| description | A high percentage of malignant gliomas are infected by human cytomegalovirus (HCMV), and the endogenous expression of HCMV genes and their products are found in these tumors. HCMV antigen expression and its implications in gliomagenesis have emerged as a promising target for adoptive cellular immunotherapy (ACT) strategies in glioblastoma multiforme (GB) patients. Since antigen-specific T cells in the tumor microenvironments lack efficient anti-tumor immune response due to the immunosuppressive nature of glioblastoma, CMV-specific ACT relies on in vitro expansion of CMV-specific CD8+ T cells employing immunodominant HCMV antigens. Given the fact that several hurdles remain to be conquered, recent clinical trials have outlined the feasibility of CMV-specific ACT prior to tumor recurrence with minimal adverse effects and a substantial improvement in median overall survival and progression-free survival. This review discusses the role of HCMV in gliomagenesis, disease prognosis, and recent breakthroughs in harnessing HCMV-induced immunogenicity in the GB tumor microenvironment to develop effective CMV-specific ACT. |
| first_indexed | 2024-12-12T21:31:43Z |
| format | Article |
| id | doaj.art-ae4990c73c7d412abe4cdbb3f914d62c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T21:31:43Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ae4990c73c7d412abe4cdbb3f914d62c2022-12-22T00:11:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.818447818447The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma MultiformeAmin Daei Sorkhabi0Amin Daei Sorkhabi1Aila Sarkesh2Aila Sarkesh3Hossein Saeedi4Faroogh Marofi5Mahnaz Ghaebi6Nicola Silvestris7Behzad Baradaran8Behzad Baradaran9Oronzo Brunetti10Student Research Committee, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranStudent Research Committee, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranDepartment of Hematology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, IranCancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, IranMedical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, ItalyImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, IranNeurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, IranMedical Oncology Unit-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori “Giovanni Paolo II” of Bari, Bari, ItalyA high percentage of malignant gliomas are infected by human cytomegalovirus (HCMV), and the endogenous expression of HCMV genes and their products are found in these tumors. HCMV antigen expression and its implications in gliomagenesis have emerged as a promising target for adoptive cellular immunotherapy (ACT) strategies in glioblastoma multiforme (GB) patients. Since antigen-specific T cells in the tumor microenvironments lack efficient anti-tumor immune response due to the immunosuppressive nature of glioblastoma, CMV-specific ACT relies on in vitro expansion of CMV-specific CD8+ T cells employing immunodominant HCMV antigens. Given the fact that several hurdles remain to be conquered, recent clinical trials have outlined the feasibility of CMV-specific ACT prior to tumor recurrence with minimal adverse effects and a substantial improvement in median overall survival and progression-free survival. This review discusses the role of HCMV in gliomagenesis, disease prognosis, and recent breakthroughs in harnessing HCMV-induced immunogenicity in the GB tumor microenvironment to develop effective CMV-specific ACT.https://www.frontiersin.org/articles/10.3389/fonc.2022.818447/fullimmunotherapyadoptive cellular therapy (ACT)CMV-specific T cellcytomegalovirus (CMV)herpes virusglioblastoma multiforme |
| spellingShingle | Amin Daei Sorkhabi Amin Daei Sorkhabi Aila Sarkesh Aila Sarkesh Hossein Saeedi Faroogh Marofi Mahnaz Ghaebi Nicola Silvestris Behzad Baradaran Behzad Baradaran Oronzo Brunetti The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme Frontiers in Oncology immunotherapy adoptive cellular therapy (ACT) CMV-specific T cell cytomegalovirus (CMV) herpes virus glioblastoma multiforme |
| title | The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme |
| title_full | The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme |
| title_fullStr | The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme |
| title_full_unstemmed | The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme |
| title_short | The Basis and Advances in Clinical Application of Cytomegalovirus-Specific Cytotoxic T Cell Immunotherapy for Glioblastoma Multiforme |
| title_sort | basis and advances in clinical application of cytomegalovirus specific cytotoxic t cell immunotherapy for glioblastoma multiforme |
| topic | immunotherapy adoptive cellular therapy (ACT) CMV-specific T cell cytomegalovirus (CMV) herpes virus glioblastoma multiforme |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.818447/full |
| work_keys_str_mv | AT amindaeisorkhabi thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT amindaeisorkhabi thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT ailasarkesh thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT ailasarkesh thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT hosseinsaeedi thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT farooghmarofi thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT mahnazghaebi thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT nicolasilvestris thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT behzadbaradaran thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT behzadbaradaran thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT oronzobrunetti thebasisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT amindaeisorkhabi basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT amindaeisorkhabi basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT ailasarkesh basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT ailasarkesh basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT hosseinsaeedi basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT farooghmarofi basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT mahnazghaebi basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT nicolasilvestris basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT behzadbaradaran basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT behzadbaradaran basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme AT oronzobrunetti basisandadvancesinclinicalapplicationofcytomegalovirusspecificcytotoxictcellimmunotherapyforglioblastomamultiforme |